Ana Alfirevic
Overview
Explore the profile of Ana Alfirevic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
2136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel W, Shankar R, Smith M, Snodgrass H, Pirmohamed M, Jorgensen A, et al.
Mol Pharm
. 2024 Jan;
21(2):550-563.
PMID: 38261609
4-Chlorokynurenine (4-Cl-KYN, AV-101) is a prodrug of a NMDA receptor antagonist and is in clinical development for potential CNS indications. We sought to further understand the distribution and metabolism of...
2.
Editorial: Emerging talents in frontiers in pharmacology: pharmacogenetics and pharmacogenomics 2022
Klomp S, Alfirevic A
Front Pharmacol
. 2023 Nov;
14:1307602.
PMID: 38026952
No abstract available.
3.
Monangi N, Xu H, Fan Y, Khanam R, Khan W, Deb S, et al.
Am J Clin Nutr
. 2023 Oct;
119(1):221-231.
PMID: 37890672
Background: Copper (Cu), an essential trace mineral regulating multiple actions of inflammation and oxidative stress, has been implicated in risk for preterm birth (PTB). Objectives: This study aimed to determine...
4.
Ball A, Jolly C, Lennon M, Lyon J, Alfirevic A, Chadwick A
Elife
. 2023 Jun;
12.
PMID: 37278519
Background: Evidence supports an important link between mitochondrial DNA (mtDNA) variation and adverse drug reactions such as idiosyncratic drug-induced liver injury (iDILI). Here, we describe the generation of HepG2-derived transmitochondrial...
5.
Bin Dayel F, Alfirevic A, Chadwick A
Biomedicines
. 2023 May;
11(5).
PMID: 37239154
The United States Food and Drug Administration Adverse Event Reporting System (FAERS) logged 27,140 rhabdomyolysis cases from 2004 to 31 March 2020. We used FAERS to identify 14 drugs frequently...
6.
Jaruthamsophon K, Thomson P, Hammond S, Zhang E, Alfirevic A, Sukasem C, et al.
Chem Res Toxicol
. 2023 Apr;
36(5):757-768.
PMID: 37074725
Carbamazepine (CBZ) is an aromatic anticonvulsant known to cause drug hypersensitivity reactions, which range in severity from relatively mild maculopapular exanthema to potentially fatal Stevens-Johnson syndrome and toxic epidermal necrolysis...
7.
Downing J, Taylor R, Mountain R, Barr B, Daras K, Comerford T, et al.
BMJ Open
. 2022 May;
12(5):e054584.
PMID: 35613765
Objectives: To examine the socioeconomic and demographic drivers associated with polypharmacy (5-9 medicines), extreme polypharmacy (9-20 medicines) and increased medication count. Design, Setting And Participants: A total of 5509 participants,...
8.
9.
Gupta J, Care A, Goodfellow L, Alfirevic Z, Muller-Myhsok B, Alfirevic A
Sci Rep
. 2022 Feb;
12(1):1986.
PMID: 35105937
No abstract available.
10.
Gupta J, Care A, Goodfellow L, Alfirevic Z, Muller-Myhsok B, Alfirevic A
Sci Rep
. 2022 Jan;
12(1):1003.
PMID: 35046466
Preterm birth (PTB) occurs before 37 weeks of gestation. Risk factors include genetics and infection/inflammation. Different mechanisms have been reported for spontaneous preterm birth (SPTB) and preterm birth following preterm...